Uppsala, Sweden – May 12, 2014 - The bond process announced in the Q1 Interim Report on April 25, 2014, and confirmed in a separate release on April 30, 2014, has now been successfully completed and the proceeds have been made available to Orexo. The full terms and conditions of the bonds can be found on the company’s website, www.orexo.com.
For additional information, please contact: Henrik Juuel, CFO and EVP, Orexo AB Phone: +46 (0)72-220 94 77, E-mail: firstname.lastname@example.org
Daniel Gabriel, Corporate Finance, Pareto Securities Phone: +46 (0)8-402 51 95, E-mail: email@example.com
About Orexo Orexo is a specialty pharma company with commercial operations in the United States and R&D in Sweden developing improved treatments using proprietary drug delivery technology and commercial operations in the United States. The company is commercializing its proprietary product, Zubsolv®, for maintenance treatment of opioid dependence, in the United States. Zubsolv is a novel formulation of buprenorphine and naloxone using Orexo’s extensive knowledge in sublingual technologies. Orexo has a portfolio of two approved and revenue generating products currently marketed under license in the EU and US. Orexo AB, with its headquarters in Sweden, is listed on NASDAQ OMX Stockholm Exchange and its American Depositary Receipts (ADRs) trade on the OTCQX marketplace in the U.S. under the symbol, “ORXOY”. The largest shareholders are Novo A/S and HealthCap.
For information about Orexo, please visit www.orexo.com
This information was brought to you by Cision http://news.cision.com
The following files are available for download: